Alchimia

MARCH 16, 2016

Finally, cannabinoids improve mood, appetite and sleep while reducing stress, anxiety and agressiveness. Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study. Published in Frontiers in Pharmacology magazine, March 2014. See studies #2, 3, 4).

Cannabinoids 76

Cannabinoids Research and Development Treatment Patients 76

Freedom Leaf

OCTOBER 15, 2018

On July 23, the World Health Organization’s Expert Committee on Drug Dependence stated that “no public health problems have been associated with CBD use” and that “CBD has been found to be generally well tolerated with a good safety profile.” If you enjoyed this Freedom Leaf article, subscribe to the magazine today!

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Cannabis Law Report

SEPTEMBER 23, 2019

Therefore, the AAFP advocates for further research into the overall safety and health effects of recreational use, as well as the effects of those laws on patient and societal health. The AAFP supports requirements testing current marijuana and cannabinoid products for safety, dosing, and product consistency. In the Exam Room.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

Cannabis Law Report

AUGUST 23, 2022

I want to sleep under the stars while microdosing. And I want Silo’s clients to enjoy this God-given luxury that experienced psychedelic users can do on their own, but in the safety and comfort of secure accommodations under the cover our of risk mitigation protocols.” I want to hear a tropical storm.

Microdosing 52

Microdosing Therapy Media Conditions 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Our research focuses on discourse about cannabis in several major medical journals and magazines for Australian doctors.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

JUNE 4, 2021

David John Nutt is an English neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep. Through its discovery platform, Delix has identified a class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

SpeedWeed

FEBRUARY 24, 2021

According to the DPA report, drug courts “have not demonstrated cost savings, reduced incarceration, or improved public safety,” but they do make “the criminal justice system more punitive toward addiction—not less; while leaving many people worse off for trying.”. The drug treatment industry’s shoddy record.

Treatment 52

Treatment Data Programs Decriminalization 52